A clinical trial publication with contributions by the Wisconsin Research and Education Network (WREN) was selected as an Editor’s Choice Clinical Trial of 2025 by the editor of JAMA Dermatology. The publication, “Emollients to Prevent Pediatric Eczema,” was highlighted throughout April 2026 on the JAMA+ Trials homepage in a feature exploring crosscutting innovations, challenges, and trends in trials research.
WREN was one of four practice-based research networks in the Meta-network Learning and Research Center that participated in the Community-based Assessment of Skin Care, Allergies, and Eczema (CASCADE) trial. WREN recruited five primary care clinics in Wisconsin and worked with clinics to develop strategies to successfully enroll parent-baby dyads. WREN research coordinators conducted study activities, including abstracting participants’ medical records to determine outcome measures.
The CASCADE trial was designed to determine if daily, full-body application moisturizer initiated within the first nine weeks of life reduced the two-year cumulative incidence eczema in infants. The results showed that infants assigned to the daily moisturizer group had a lower cumulative incidence of eczema compared with the those in the standard of care group.
WREN is a statewide practice-based research network with hundreds of primary care clinicians and academic researchers. The network conducts high-quality translational research projects in real-world family practices across Wisconsin.
JAMA, the Journal of the American Medical Association, is the most widely circulated general medical journal in the world. It has been published continuously since 1883. JAMA Dermatology is a member of the JAMA Network, a consortium of peer-reviewed, general medical, and specialty publications.
Published: May 2026